Tobacco companies finally have to say smoking causes cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

These statements may not be breaking news for oncologists and other physicians, who should have been aware of the lethal nature of cigarette smoking at least since the publication of the first Surgeon General’s report on Smoking and Health more than half a century ago. While the report generated front page headlines and led the network newscasts back in January 1964, the tobacco epidemic has continued, causing more than 20 million deaths in the U.S. in the decades since. Cigarette companies have persisted in using their legal, marketing, and propaganda tools to mislead and addict millions of consumers, including underage youth, for the sole purpose of increasing profits.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
Cliff Douglas
Vice President for Tobacco Control at the American Cancer Society and an attorney
with 30 years’ experience in tobacco control advocacy and litigation.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login